The nine-year sustained cost-containment impact of Swiss pilot physicians-pharmacists quality circles

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 650-657

  Niquille, Anne ^a   Ruggli, Martine ^b   Buchmann, Michel ^c   Jordan, Dominique ^b   Bugnon, Olivier ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Swiss Association of Pharmacists   (Switzerland)

^c Pharmacy Tête Noire ^*  (Switzerland)

Author keywords

Community pharmacy services; Cost containment; Drug prescription; Implementation; Patient care team; Quality of health care Switzerland

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; ATTITUDE; CLINICAL PHARMACY; COMMUNITY; COMPARATIVE STUDY; CONTINUING EDUCATION; CONTROL GROUP; COST CONTROL; DRUG CHOICE; DRUG COST; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEEDBACK SYSTEM; GENERAL PRACTITIONER; HEALTH CARE; HEALTH CARE COST; HEALTH EDUCATION; HEALTH INSURANCE; INTERVENTION STUDY; MARKETING; MEDICAL LITERATURE; PATIENT SAFETY; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CIRCLE; TOTAL QUALITY MANAGEMENT;

COST CONTROL; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; DRUG PRESCRIPTIONS; DRUGS, GENERIC; GUIDELINES AS TOPIC; HUMANS; MANAGEMENT QUALITY CIRCLES; MARKETING; PHARMACIES; PHARMACISTS; PHYSICIANS; PILOT PROJECTS; QUALITY OF HEALTH CARE; SWITZERLAND;

EID: 77950525996     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M537     Document Type: Article

References (31)

1. Committee on Quality of Health Care in America IoM. Crossing the quality chasm: a new health system for the 21st century. www.nap.edu/catalog.php?record- id=10027#toc (accessed 2009 Jul 20).
2. The World Health Organisation (WHO). Preparing a healthcare workforce for the 21st century: the challenge of chronic conditions. Chronic Illness 2005;1:99-100.
3. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-465 (Pubitemid 36119966)
4. Okike K, Kocher MS, Mehlman CT, Bhandari M. Industry-sponsored research. Injury 2008;39:666-680
5. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 2002;325:249-252 (Pubitemid 34864391)
6. Dybdahl T, Andersen M, Kragstrup J, Kristiansen IS, Sondergaard J. General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study. Br J Clin Pharmacol 2005;60:526-533 (Pubitemid 41532453)
7. Freemantle N, Johnson R, Dennis J, Kennedy A, Marchment M. Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice. Br J Clin Pharmacol 2000;49:174-179 (Pubitemid 30068296)
8. Schowalter JE. How to manage conflicts of interest with industry? Int Rev Psychiatry 2008;20:127-133
9. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A National survey of physician-industry relationships. N Engl J Med 2007;356:1742-1750 (Pubitemid 46658706)
10. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408-416 (Pubitemid 27384745)
11. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-72. (Pubitemid 38279464)
12. Bugnon O, Niquille A, Repond C, Curty C, Nyffeler R. Les cercles de qualités médecins-pharmaciens: un réseau local reconnu pour maîtriser les coûts et la qualité de la prescription médicale. Médecine Hygiène 2004;62:2054-2058
13. Essential Drugs Monitor editors. Swiss Quality Circles: improving health care, reducing costs (abstract). Essential Drugs Monitor 2001;30:22.
14. Locca JF, Ruggli M, Buchmann M, Huguenin J, Bugnon O. Development of pharmaceutical care services in nursing homes: practice and research in a Swiss canton. Pharm World Sci 2009;31:165-173
15. Guignard E, Bugnon O. Pharmaceutical care in community pharmacies: practice and research in Switzerland. Ann Pharmacother 2006;40:512-517 DOI 10.1345/aph.1G199
16. Grindrod KA, Patel P, Martin JE. What interventions should pharmacists employ to impact health practitioners' prescribing practices? Ann Pharmacother 2006;40:1546-1557 DOI 10.1345/aph.1G300 (Pubitemid 44330199)
17. Ostini R, Hegney D, Jackson C, et al. Systematic review of interventions to improve prescribing. Ann Pharmacother 2009;43:502-513 DOI 10.1345/aph.1L488
18. Ruggli M. Quality improvement of primary care prescription efficiency by cooperating in quality circles physicians-pharmacists. Presented at: World Congress of Pharmacy and Pharmaceutical Sciences-64th Congress of Federation Internationale Pharmaceutic, New Orleans, September 9, 2004.
19. Ruggli M, Decollogny A, Niquille A, Buchmann M, Bugnon O. Impact of the physicians-pharmacists quality circles on the prenetration of generics. Presented at: World Congress of Pharmacy and Pharmaceutical Sciences-66th Congress of Federation Internationale Pharmaceutic, Salvador de Bahia, August 27, 2006.
20. Confédération suisse. Office fédérale de la Statistique (OFS). www.bfs.admin.ch/bfs/portal/fr/index.html (accessed 2009 July 16).
21. Coopérative professionnelle pour les pharmaciens suisses (OFAC). www.ofac.ch (accessed 2009 July 24).
22. The World Health Organisation (WHO). ATC code. www.whocc.no/atcddd (accessed 2009 July 10).
23. von Ferber L, Bausch J, Koster I, Schubert I, Ihle P. Pharmacotherapeutic circles. Results of an 18-month peer-review prescribing-improvement programme for general practitioners. Pharmacoeconomics 1999;16:273-283 (Pubitemid 29434155)
24. Ashworth M, Armstrong D, Lloyd D, Colwill S. The effects on GP prescribing of joining a commissioning group. J Clin Pharm Ther 2002;27: 221-228 (Pubitemid 34748148)
25. Lundborg CS, Wahlstrom R, Diwan VK, Oke T, Martenson D, Tomson G. Combining feedback from simulated cases and prescribing. Design and implementation of an educational intervention in primary care in Sweden. Int J Technol Assess Health Care 1999;15:458-472 (Pubitemid 29466179)
26. Lagerlov P, Loeb M, Andrew M, Hjortdahl P. Improving doctors' prescribing behaviour through reflection on guidelines and prescription feedback: a randomised controlled study. Qual Health Care 2000;9:159-165
27. Le marché du médicament en Suisse. www.Interpharma.ch (accessed 2009 July 3)
28. Parfrey PS. Inhibitors of the renin-angiotensin system: proven benefits, unproven safety. Ann Intern Med 2008;148:76-77
29. Andersen M. Is it possible to measure prescribing quality using only prescription data? Basic Clin Pharmacol Toxicol 2006;98:314-319
30. de Vries CS, Tromp TF, Blijleven W, de Jong-van den Berg LT. Prescription data as a tool in pharmacotherapy audit (I). General considerations. Pharm World Sci 1999;21:80-84 (Pubitemid 29251953)
31. Santschi V, Rodondi N, Bugnon O, Burnier M. Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. Eur J Intern Med 2008;19:427-434